Abstract
This clinical trial (NCT03502629, registered April 18, 2018) investigated the efficacy and safety of geptanolimab (GB226), a novel anti-PD-1 antibody, in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). In this multicenter Phase 2 study, geptanolimab demonstrated a promising objective response rate (ORR) of 40.4% and a manageable safety profile, particularly in patients with high PD-L1 expression.
Introduction
Peripheral T-cell lymphoma (PTCL) represents a heterogeneous and aggressive group of non-Hodgkin lymphomas characterized by poor clinical outcomes. While frontline chemotherapy regimens like CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) are standard, a significant proportion of patients experience relapse or refractory disease. For these individuals, second-line treatment options are limited, often yielding response rates below 30%.
The application of immune checkpoint inhibitors, specifically anti-PD-1 antibodies, has been transformative in many malignancies. However, their utility in T-cell lymphomas has remained controversial due to concerns that PD-1 blockade might inadvertently accelerate disease progression—a phenomenon known as hyperprogression—in certain T-cell subtypes. The Gxplore-002 study was designed to evaluate the clinical potential of geptanolimab in this challenging patient population.
Methods
Gxplore-002 was a single-arm, multicenter Phase 2 clinical trial conducted across 41 sites in China. The study enrolled 102 patients with relapsed or refractory PTCL. Participants received geptanolimab at a dose of 3 mg/kg intravenously every two weeks.
The primary efficacy endpoint was the Objective Response Rate (ORR), determined by an Independent Radiological Review Committee (IRRC) using the Lugano 2014 criteria. Secondary analyses included biomarker evaluations of PD-L1 expression (via immunohistochemistry), Tumor Mutation Burden (TMB), and Microsatellite Instability (MSI) to identify predictors of therapeutic response.
Results
Efficacy and Survival
Of the 102 patients enrolled, 89 were included in the Full Analysis Set (FAS) following central histological confirmation. The IRRC-assessed ORR was 40.4% (95% CI: 30.2–51.4), comprising 13 complete responses (14.6%) and 23 partial responses (25.8%).
The median duration of response (DOR) was 11.4 months, indicating that responses to geptanolimab are often durable. For the entire FAS cohort, the median Progression-Free Survival (PFS) was 2.7 months, and the median Overall Survival (OS) reached 14.6 months.
Biomarker Correlation and Subtype Sensitivity
A key finding of the study was the significant correlation between PD-L1 expression and clinical benefit. Patients with high PD-L1 expression (≥ 50%) achieved an ORR of 53.3%, compared to 25.0% in the low-expression group. Furthermore, the median PFS in the PD-L1 high group was extended to 6.2 months.
Response rates also varied by PTCL subtype. Notably, patients with extranodal NK/T-cell lymphoma (ENKTL) showed a high sensitivity to geptanolimab, with an ORR of 63.2%.
Safety Profile
Geptanolimab demonstrated a manageable safety profile. Treatment-related adverse events (TRAEs) of Grade 3 or higher occurred in 25.5% of the safety population (n=102), primarily manifesting as hematological toxicities such as decreased white blood cell or platelet counts. While serious adverse events (SAEs) occurred in 44.1% of patients, only 18.6% were attributed to the study drug. Importantly, the trial did not observe widespread hyperprogressive disease, addressing a major concern regarding PD-1 inhibition in T-cell lymphomas.
Discussion
The Gxplore-002 study provides robust evidence that geptanolimab is an effective and safe option for patients with relapsed or refractory PTCL. The high response rates in the ENKTL subtype and the strong predictive value of PD-L1 expression (≥ 50%) offer a clear strategy for patient selection in clinical practice.
Despite these positive results, the study has limitations, including its single-arm design and relatively short median follow-up (4.06 months). Additionally, as the trial was conducted exclusively in China, further global studies are necessary to validate these findings across different geographic populations where PTCL subtype prevalence may differ.
Conclusion
Geptanolimab (GB226) represents a significant advancement in the immunotherapy landscape for r/r PTCL. Future randomized controlled trials with extended follow-up are warranted to further define its role in the standard of care for this aggressive disease.
Summary updated